FDA CDER Small Business and Industry Assistance (SBIA) Chronicles

Nov 14 2024 15 ep. 8 mins 3
FDA CDER Small Business and Industry Assistance (SBIA) Chronicles Podcast artwork

FDA’s Center for Drug Evaluation and Research Small Business and Industry Assistance (SBIA) podcast provides industry with brief synopses of trending regulatory information.

  Health & Fitness  Science  Government
RSS feed Share
Copy RSS


Subscribe on Podcast Addict


Audio Transcript | The Need for Artificial Intelligence in Pharmacovigilance with Dr. Robert Ball

Nov 14 2024 11 mins  
Audio podcast for the pharmaceutical industry on The Need for Artificial Intelligence in Pharmacovigilance and the Emerging Drug Safety Technology Program

Considerations for Drug Products that Contain Nanomaterials

May 15 2024 11 mins  
Considerations for Drug Products that Contain Nanomaterials

Using Bayesian statistical approaches to advance our ability to evaluate drug products

Aug 17 2023 7 mins  
Using Bayesian statistical approaches to advance our ability to evaluate drug products

Insights About the FDA/EMA Parallel Scientific Advice Program for Complex Generic/Hybrid Drug Products

Jul 10 2023 7 mins  
Insights About the FDA/EMA Parallel Scientific Advice Program for Complex Generic/Hybrid Drug Products

The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development

Apr 09 2023 9 mins  
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development

FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds

Feb 06 2023 11 mins  
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds

The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities

Sep 28 2022 7 mins  
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities

An FDA Self-Audit of Continuous Manufacturing for Drug Products

Jun 27 2022 11 mins  
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.

The Key Elements of Being “Recall-Ready”

Apr 19 2022 7 mins  
A voluntary recall is an action taken by a company to correct a violative product or remove it from the market.

The ABCs of Product Specific Guidances

Sep 02 2021 7 mins  
Product-specific guidances (or PSGs for short) describe the Agency's current thinking on the evidence needed to demonstrate that a generic drug is therapeutically equivalent to the corresponding reference listed drug (RLD) product.